Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I:

$$R_1$$
 R_2
 R_3
 R_4
 R_5
 R_6
 R_6

wherein R_1 and R_2 are each independently H, <u>or cyclopropyl</u> alkyl, cycloalkyl, aryl, heteroaryl, $-C(O)R_Z$, $-OR_Z$ or $-C(O)NR_ZR_B$, wherein the <u>cyclopropyl</u> alkyl, cycloalkyl, aryl and heteroaryl groups group may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, $-OR_7$, a heteroalicyclic group, and a trihaloalkyl group;

 R_3 and R_4 are each independently selected from the group consisting of H, halo, alkyl, aryl, heteroaryl, heteroalicylic, -OH, OR_z , $-NR_zR_8$, $-(CH_2)_nC(O)OR_z$, $-SO_2R_{z_7}$, $-(CH_2)_nC(O)NR_zR_8$, $-C(S)NR_zR_8$, $-C(O)R_z$, $-NR_zC(O)R_8$, $-NHC(O)OR_8$, $-NR_zC(O)NR_9R_8$, $-SO_2NR_zR_8$, $-OC(O)OR_z$, $-OC(O)NR_zR_8$, $-OC(O)NR_zR_8$, $-OC(O)NR_zR_8$, $-OC(O)NR_zR_8$, $-OC(O)OR_z$,

 R_5 is <u>phenyl</u> selected from the group consisting of H, aryl, or halo, wherein the <u>phenyl</u> aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

wherein at least one of R_3 , R_4 and R_5 is an aryl;

R₆ is H;

R₇, R₈ and R₉ are independently H, alkyl, aralkyl, heterocycloalkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, –OH, alkoxy, amino, –NO₂ and -CN;

alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than 4 of the heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with

Serial No. 10/781,928 Conf. No. 9693 one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicylic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3; wherein one of R_1 or R_2 is cyclopropyl; or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Withdrawn) A compound of formula I:

$$R_1$$
 R_2 R_3 R_4 R_5 R_6 R_6

wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, -C(O) R_7 , -O R_7 or -C(O) NR_7R_8 wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, -OR $_7$, a heteroalicyclic group, and a trihaloalkyl group;

 R_3 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R₄ is H:

 R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

 R_6 is H;

 R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, -OH, alkoxy, amino, $-NO_2$ and -CN;

alternatively, NR_7R_8 can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR_7R_8 may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, heteroalicylic, aryl, heteroaryl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

4. (Withdrawn) A compound of formula I:

$$R_1$$
 R_2 R_3 R_4 R_5 R_6 R_6

wherein R_1 and R_2 are each independently H, alkyl, cycloalkyl, aryl, heteroaryl, -C(O) R_7 , -O R_7 or -C(O) NR_7R_8 wherein the alkyl, cycloalkyl, aryl and heteroaryl groups may be further substituted with one or more substituents selected from the group consisting of aryl, halogen, -OH, -OR $_7$, a heteroalicyclic group, and a trihaloalkyl group;

R₃ is H;

 R_4 is aryl, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

 R_5 is selected from the group consisting of H, aryl or halo, wherein the aryl group may be further substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halogen, hydroxy or protected hydroxy, $-OR_7$, $-NR_7R_8$, $-NR_7C(O)R_8$, aryl, $-C(O)OR_7$, cycloalkyl, haloalkyl, haloalkoxy, $-C(O)R_7$, $-NR_7C(O)OR_8$, $-SO_2R_7$, $-NR_7C(O)NR_9R_8$, $-C(O)NR_7R_8$ and $-SO_2NR_7R_8$;

R₆ is H:

 R_7 , R_8 and R_9 are independently H, alkyl or aryl, wherein the alkyl and aryl may be further substituted with one or more substituents selected from the group consisting of alkyl, aryl, trifluoroalkyl, hydroxy, alkoxy, amino, $-NO_2$ and -CN;

alternatively, NR₇R₈ can form a 5 - 7 membered heteroalicyclic ring, a 5 - 6 membered heteroaryl ring, wherein the heteroalicyclic ring may further contain no more than four heteroatoms (N, O, or S), and the cyclic structure formed about NR₇R₈ may be substituted with one or more substituents selected from the group consisting of alkyl, haloalkyl, alkoxy, hydroxy, heteroalicylic, heterocycloalkyl, aryl, heteroaryl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl and halo; and

wherein n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

- (Withdrawn) The compound of claim 1, wherein R₄ and R₅ are optionally substituted aryl.
- 6. (Currently Amended) A compound selected from the group consisting of:

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

```
3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine,
```

3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,

N-[4-(4-trifluoromethyl-benzamide-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide.

N-[4-(8-Amino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-4-trifluoromethyl-benzamide,

(4-Methoxy-phenyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Dimethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Isopropyl (3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

4-(8-Isopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Butyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

(2-Morpholin-4-yl-ethyl)-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Benzyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

2-(3-Phenyl-imidazo[1,2-a]pyrazin-8-ylamino)-ethanol,

1-Butyl-3-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-urea,

N-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

N-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,

2,6-Dimethyl-4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-ylamine,

Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[3-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

Methyl-[3-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

Methyl-[3-(3-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine.

Methyl-[3-(2-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

(3-Biphenyl-2-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,

[3-(2-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[3-(3-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-tert-Butyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

[3-(4-Cyclohexyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine.

[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,

3-(8-Methylamino-imidazo[1,2-a]pyrazin-4-yl)-benzoic acid,

Methyl-(3-o-tolyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,

```
Methyl-[3-(4-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
[3-(2,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(3,4-Dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
(3-Biphenyl-4-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
(3-Biphenyl-3-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
[3-(4-Benzyloxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
Methyl-(3-naphthalen-1-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
[3-(2-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
N-[3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]acetamide,
Methyl-[3-(2-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
Methyl-[3-(3-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
Cyclopropyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
[3-(2-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine.
[3-(3,4-Difluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
(3-Benzo[1,3]dioxol-5-yl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine,
[3-(3-Chloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(4-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(2-Methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
Methyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
[3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(4-Isopropyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
[3-(3,5-Bis-trifluoromethyl-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
Cyclopropyl-[3-(3,4-dichloro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
Methyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
Cyclopropyl-{3-[4-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
Cyclopropyl-[3-(4-phenoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine.
1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,
N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-acetamide,
[3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
```

[3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine, Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,

- 4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-benzoic acid,
- [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
- Methyl-{3-[3-(2-morpholin-4-yl-ethoxy)-phenyl]-imidazo[1,2-a]pyrazin-8-yl}-amine,
- [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
- 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
- 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzamide,
- 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-morpholin-4-yl-propyl)-benzamide,
- 4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-N-(3-pyrrolidin-1-yl-propyl)-benzamide,
- 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl] 3-(3-morpholin-4-yl-propyl) urea,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3 (3-morpholin-4-yl-propyl)-urea,
- (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyll-amide,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
- 4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1 [4 (8 Methylamino imidazo[1,2 alpyrazin 3 vI) phenyl] 3 (2 morpholin 4 vI ethyl) urea,
- 4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- 4-Hydroxy-piperidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 - 1-[3 (8-Methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl]-3 (2-pyrrolidin-1-yl-ethyl) urea,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,

```
(R)-2-Dimethylaminomethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-
alpyrazin-3-yl)-phenyll-amide,
        1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyll-3-(2-pyrrolidin-1-yl-ethyl)-urea,
       (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-
yl)-phenyl]-amide,
        1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-
urea,
        1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-
urea,
        1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-
urea,
        1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-
urea,
        [5-(4-Fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
        Methyl-(5-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,
        Methyl-(5-thiophen-3-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
        4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenol,
        N-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-5-yl)-phenyl]-acetamide,
       [3,5-Bis-(4-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
```

7. (Currently Amended) A compound selected from the group consisting of:

(3,5-Diphenyl-imidazo[1,2-a]pyrazin-8-yl)-methyl-amine, Methyl-(6-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine, 4-(8-Methylamino-imidazo[1,2-a]pyrazin-6-yl)-phenol,

Methyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Dimethyl (3-phenyl-imidazo[1,2-a]pyrazin-5-yl-amine, or a prodrug or pharmaceutically acceptable salt thereof.

6-Phenyl-imidazo[1,2-a]pyrazin-8-ylamine and

4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Ethyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine,

Cyclopropyl-(3-phenyl-imidazo[1,2-a]pyrazin-8-yl)-amine.

1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,

[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyll-carbamic acid benzyl ester,

[3-(3-Fluoro-4-methoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

3-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,

Methyl-[3-(4-trifluoromethoxy-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,

[3-(4-Benzyloxy-3-fluoro-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,

- Cyclopropyl-[3-(4-dimethylamino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-amine,
- 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-ethanone,
- [4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-carbamic acid benzyl ester,
- [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
- [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
- Methyl-(3-naphthalen-2-yl-imidazo[1,2-a]pyrazin-8-yl)-amine,
- [3-(4-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-cyclopropyl-amine,
- [3-(3-Amino-phenyl)-imidazo[1,2-a]pyrazin-8-yl]-methyl-amine,
- 3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenol,
- 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (S)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl] 3 (3-morpholin-4-yl-propyl) urea,
- (S)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- (R)-2-Pyrrolidin-1-ylmethyl-pyrrolidine-1-carboxylic acid [3-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
- 4-Pyrrolidin-1-yl-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl] amide,
 - 1-[4-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
- 4-Hydroxy-piperidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea,
 - 1-[3-(8-Methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,
 - 1-[3 (8-Methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl] 3 (3-morpholin-4-yl-propyl) urea,
 - 1 [4 (8 Methylamino-imidazo[1,2-a]pyrazin-3-yl) phenyl]-3 (2-pyrrolidin-1-yl-ethyl) urea,
- (R)-3-Hydroxy-pyrrolidine-1-carboxylic acid [4-(8-methylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-amide,
- 1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-pyrrolidin-1-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(3-morpholin-4-yl-propyl)-urea,

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-pyrrolidin-1-yl-ethyl)-urea and

1-[4-(8-Cyclopropylamino-imidazo[1,2-a]pyrazin-3-yl)-phenyl]-3-(2-morpholin-4-yl-ethyl)-urea,

or a prodrug or pharmaceutically acceptable salt thereof.

8. (Withdrawn) A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt of a compound of any one of claims 1, 2, 3, 4, 5 or 6 and pharmaceutically acceptable carrier or excipient.

9-16. (Canceled)

Serial No. 10/781,928 Conf. No. 9693